scispace - formally typeset
L

Lars Bertram

Researcher at University of Lübeck

Publications -  333
Citations -  34079

Lars Bertram is an academic researcher from University of Lübeck. The author has contributed to research in topics: Genome-wide association study & Medicine. The author has an hindex of 70, co-authored 287 publications receiving 28626 citations. Previous affiliations of Lars Bertram include University of Sheffield & Max Planck Society.

Papers
More filters
Journal ArticleDOI

A comprehensive 1000 Genomes–based genome-wide association meta-analysis of coronary artery disease

Majid Nikpay, +167 more
- 07 Sep 2015 - 
TL;DR: This article conducted a meta-analysis of coronary artery disease (CAD) cases and controls, interrogating 6.7 million common (minor allele frequency (MAF) > 0.05) and 2.7 millions low-frequency (0.005 < MAF < 0.5) variants.
Journal ArticleDOI

Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective.

TL;DR: The amyloid hypothesis based on both known and putative Alzheimer's disease genes is assessed, with positive results for beta-amyloid inaques andaques is confirmed in animals and humans.
Journal ArticleDOI

Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database

TL;DR: A publicly available, continuously updated database that comprehensively catalogs all genetic association studies in the field of Alzheimer disease, and it serves as a potential model for tracking the most viable gene candidates in other genetically complex diseases.
Journal ArticleDOI

Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease

TL;DR: This article conducted a meta-analysis of Parkinson's disease genome-wide association studies using a common set of 7,893,274 variants across 13,708 cases and 95,282 controls.
Journal ArticleDOI

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.

TL;DR: An updated review of the literature and evidence on the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage of Alzheimer's disease are provided.